204 related articles for article (PubMed ID: 32402819)
1. Cost-Effectiveness Analysis of Prostate-Specific Antigen Screening Among Chinese Men.
Zhao G; Shao Y; Zhang N; Wang J; Yuan L; Sun X; Shi L
Value Health Reg Issues; 2020 May; 21():272-279. PubMed ID: 32402819
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of prostate health index for prostate cancer detection in Chinese men.
Teoh JY; Leung CH; Wang MH; Chiu PK; Yee CH; Ng CF; Wong MC
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):615-621. PubMed ID: 32606435
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Prostate Health Index for prostate cancer detection.
Nichol MB; Wu J; Huang J; Denham D; Frencher SK; Jacobsen SJ
BJU Int; 2012 Aug; 110(3):353-62. PubMed ID: 22077934
[TBL] [Abstract][Full Text] [Related]
4. A Cost-Utility Analysis of Prostate Cancer Screening in Australia.
Keller A; Gericke C; Whitty JA; Yaxley J; Kua B; Coughlin G; Gianduzzo T
Appl Health Econ Health Policy; 2017 Feb; 15(1):95-111. PubMed ID: 27757918
[TBL] [Abstract][Full Text] [Related]
5. Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
Callender T; Emberton M; Morris S; Eeles R; Kote-Jarai Z; Pharoah PDP; Pashayan N
PLoS Med; 2019 Dec; 16(12):e1002998. PubMed ID: 31860675
[TBL] [Abstract][Full Text] [Related]
6. High-resolution microendoscopy for esophageal cancer screening in China: A cost-effectiveness analysis.
Hur C; Choi SE; Kong CY; Wang GQ; Xu H; Polydorides AD; Xue LY; Perzan KE; Tramontano AC; Richards-Kortum RR; Anandasabapathy S
World J Gastroenterol; 2015 May; 21(18):5513-23. PubMed ID: 25987774
[TBL] [Abstract][Full Text] [Related]
7. Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States.
Jiao B; Gulati R; Hendrix N; Gore JL; Rais-Bahrami S; Morgan TM; Etzioni R
Value Health; 2021 Aug; 24(8):1111-1117. PubMed ID: 34372976
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of multiparametric magnetic resonance imaging and MRI-guided biopsy in a population-based prostate cancer screening setting using a micro-simulation model.
Getaneh AM; Heijnsdijk EA; de Koning HJ
Cancer Med; 2021 Jun; 10(12):4046-4053. PubMed ID: 33991077
[TBL] [Abstract][Full Text] [Related]
10. Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.
Pataky R; Gulati R; Etzioni R; Black P; Chi KN; Coldman AJ; Pickles T; Tyldesley S; Peacock S
Int J Cancer; 2014 Aug; 135(4):939-47. PubMed ID: 24443367
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of prostate cancer screening using the Stockholm3 test.
Karlsson AA; Hao S; Jauhiainen A; Elfström KM; Egevad L; Nordström T; Heintz E; Clements MS
PLoS One; 2021; 16(2):e0246674. PubMed ID: 33630863
[TBL] [Abstract][Full Text] [Related]
12. Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis.
Martin AJ; Lord SJ; Verry HE; Stockler MR; Emery JD
Med J Aust; 2013 Jun; 198(10):546-50. PubMed ID: 23725269
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer.
Barnett CL; Davenport MS; Montgomery JS; Wei JT; Montie JE; Denton BT
BJU Int; 2018 Jul; 122(1):50-58. PubMed ID: 29388388
[TBL] [Abstract][Full Text] [Related]
14. [Socioeconomic advantages of longer screening intervals for men with low prostate-specific antigen levels in prostate cancer mass screening].
Kobayashi T; Goto R; Hinotsu S; Ogawa O
Hinyokika Kiyo; 2013 Mar; 59(3):159-66. PubMed ID: 23633630
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results.
Yun H; Kim J; Gandhe A; Nelson B; Hu JC; Gulani V; Margolis D; Schackman BR; Jalali A
JAMA Netw Open; 2023 Nov; 6(11):e2344856. PubMed ID: 38019516
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Prostate Cancer Screening in Brazil.
Oliveira RAR; Mourão TC; Santana TBM; Favaretto RL; Zequi SC; Guimarães GC
Value Health Reg Issues; 2021 Dec; 26():89-97. PubMed ID: 34146776
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
Booth N; Rissanen P; Tammela TLJ; Kujala P; Stenman UH; Taari K; Talala K; Auvinen A
PLoS One; 2019; 14(11):e0224479. PubMed ID: 31689326
[TBL] [Abstract][Full Text] [Related]
18. Assessment of harms, benefits, and cost-effectiveness of prostate cancer screening: A micro-simulation study of 230 scenarios.
Getaneh AM; Heijnsdijk EAM; Roobol MJ; de Koning HJ
Cancer Med; 2020 Oct; 9(20):7742-7750. PubMed ID: 32813910
[TBL] [Abstract][Full Text] [Related]
19. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.
Roth JA; Gulati R; Gore JL; Cooperberg MR; Etzioni R
JAMA Oncol; 2016 Jul; 2(7):890-8. PubMed ID: 27010943
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
[Next] [New Search]
